Comparative Pharmacology
Head-to-head clinical analysis: OMNIPAQUE 140 versus OMNIPAQUE 70.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMNIPAQUE 140 versus OMNIPAQUE 70.
OMNIPAQUE 140 vs OMNIPAQUE 70
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Radiopaque contrast agent that attenuates X-rays due to iodine content, enhancing vascular and tissue visualization.
Iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast by increasing the density of blood vessels and organs.
Intravascular: 50-200 mL (containing 7.0-28.0 g iodine) per procedure, administered intravenously as a bolus or infusion; dose depends on imaging modality and body region. Intrathecal: 6-15 mL (containing 0.84-2.1 g iodine) administered via lumbar puncture for myelography.
1.5-2.0 mL/kg IV for contrast enhanced CT, max 150 mL; intra-arterial: 5-40 mL per injection depending on procedure.
None Documented
None Documented
Terminal elimination half-life: 1–2 hours; prolonged in renal impairment (up to 30–40 hours in severe dysfunction).
Terminal elimination half-life: 1-2 hours in normal renal function; prolonged in renal impairment (up to 20-30 hours in severe dysfunction).
Renal: >95% unchanged via glomerular filtration; biliary/fecal: negligible (<1%).
Renal: 100% unchanged via glomerular filtration. No biliary or fecal elimination.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent